89 Results for "

CYP inhibition

" in MedChemExpress (MCE) Product Catalog:
Products (89)

89 Results for "CYP inhibition" in MCE Product Catalog:

21
21 Publications Verification
Cat. No.: HY-N0382
CAS No.: 548-83-4
Synonyms: Norizalpinin; 3,5,7-Trihydroxyflavone
Galangin (Norizalpinin) is an agonist/antagonist of the arylhydrocarbon receptor. Galangin (Norizalpinin) also shows inhibition of CYP1A1 activity.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N0904
CAS No.: 39262-14-1
Synonyms: Ginsenoside compound K; Ginsenoside K
Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15163
CAS No.: 1204918-72-8
Synonyms: TG02; SB1317
Target:  

JAK CDK FLT3

Research Areas:  

Cancer

Zotiraciclib (TG02; SB1317) is an orally active JAK2/FLT3/CDK2 inhibitor with IC50 values of 13 nM, 73 nM and 56 nM , respectively. Zotiraciclib inhibits cancer cell proliferation, tumor growth and the activity of CYP2D6. Zotiraciclib exhibits high plasma protein binding rate, Caco-2 permeability and tissue distribution capacity, as well as metabolic stability in human and canine liver microsomes. Zotiraciclib achieves tumor growth inhibition in nude mouse models of colon cancer and lymphoma xenografts. Zotiraciclib can be used for research related to colon cancer, B-cell lymphoma, advanced leukemia, acute leukemia and multiple myeloma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-50845
CAS No.: 1146699-66-2
Synonyms: BMS-708163
Target:  

γ-secretase Notch

Research Areas:  

Cancer

Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15565
CAS No.: 832714-46-2
Purity:  99.73%
Research Areas:  

Metabolic Disease

APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC50s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (Ki=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0598
CAS No.: 53963-43-2
Synonyms: 20(S)-Ginsenoside F1
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15566
CAS No.: 897732-93-3
Purity:  99.97%
Synonyms: JNJ-38431055
Target:  

GPR119

Research Areas:  

Metabolic Disease

APD597 (JNJ-38431055) is an orally active agonist of GPR119. APD597 exhibits reduced CYP2C9 inhibition with an IC50 of 5.8 μM. APD597 can be studied in research for type 2 diabetes .
loading...
    loading...
Cat. No.: HY-134772
CAS No.: 909561-15-5
Purity:  98.10%
Target:  

STAT Cytochrome P450

Research Areas:  

Inflammation/Immunology

AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research .
loading...
    loading...
Cat. No.: HY-157421
CAS No.: 2847156-05-0
Target:  

NAMPT

Research Areas:  

Metabolic Disease

Nampt activator-4 is an orally active NAMPT activator, with an EC50 of 58 nM and a Ka of 85.38 nM against human NAMPT. Nampt activator-4 effectively relieves the feedback inhibition of nicotinamide and NAD +, thereby enhancing enzymatic activity and significantly increasing intracellular NAD + levels. Nampt activator-4 exhibits moderate stability in human and mouse liver microsomes. Nampt activator-4 shows low to moderate inhibitory effects on cytochrome P450 (especially CYP3A4). Nampt activator-4 can be used for the research of type 2 diabetes and related metabolic disorders .
loading...
    loading...
Cat. No.: HY-110079
CAS No.: 519178-28-0
Purity:  99.29%
Target:  

IPK Superfamily

Research Areas:  

Cancer

TNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC50s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization[1][2][3].
loading...
    loading...
Cat. No.: HY-W019847
CAS No.: 76530-44-4
Target:  

Cytochrome P450

Research Areas:  

Infection Metabolic Disease

Azamulin is an irreversible, highly selective inhibitior of human CYP3Aa. Azamulin has CYP3A inhibition activity with IC50 values range from 0.03-0.24 μM. Azamulin can be used for the research of metabolism and antiinfection .
loading...
    loading...
Cat. No.: HY-145786
CAS No.: 2486052-18-8
Purity:  99.69%
Target:  

Cytochrome P450

Research Areas:  

Cancer

Abiraterone decanoate is a potent Abiraterone proagent. Abiraterone decanoate provide a controlled release of Abiraterone and long-acting CYP17 inhibition with intramuscular (IM) delivery .
loading...
    loading...
Cat. No.: HY-139984
CAS No.: 2247614-80-6
Purity:  99.85%
Synonyms: BIIB091
Target:  

Btk

Corubrutinib (BIIB091) is an orally active BTK inhibitor with an IC50 of <0.5 nM, Kd of 0.07 nM, and >500-fold kinome selectivity. Corubrutinib suppresses B cell activation, proliferation, differentiation, antibody production, antigen presentation, cytokine secretion, and myeloid cell effector functions. Corubrutinib exhibits favorable pharmacokinetic and preclinical safety profiles, including low genotoxic potential, minimal hepatotoxicity, and no major transporter or CYP inhibition. Corubrutinib can be used for the research of multiple sclerosis .
loading...
    loading...
Cat. No.: HY-175746
CAS No.: 3036141-78-0
Target:  

CX3CR1

Research Areas:  

Cardiovascular Disease

AZD0233 is an orally active CX3CR1 antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research .
loading...
    loading...
Cat. No.: HY-152118
CAS No.: 2685779-55-7
Purity:  99.09%
Target:  

Cytochrome P450

Research Areas:  

Cancer

CYP1B1-IN-4 is a 2,4-diarylthiazole compound with selectively CYP1B1 inhibition (IC50=0.2 nM). CYP1B1-IN-4 has little cytotoxicity and high stability in both human and rat liver microsomes .
loading...
    loading...
Cat. No.: HY-135560
CAS No.: 494-04-2
Purity:  99.92%
Synonyms: Nicotellin
Target:  

Cytochrome P450

Research Areas:  

Neurological Disease

Nicotelline (Nicotellin) is a nicotine-related alkaloid, as well as a weak inhibitor of human cDNA-expressed cytochrome P-450 2A6 (CYP2A6). CYP2A6 mediates coumarin 7-hydroxylation, while Nicotelline fails to exhibit inhibition at 300 μM. Nicotelline can be used as a tracer and biomarker of particulate matter (PM) derived from tobacco smoke .
loading...
    loading...
Cat. No.: HY-15996
CAS No.: 1610537-15-9
Synonyms: VT-464
Research Areas:  

Cancer

Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) and an AR antagonist. Seviteronel demonstrates both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.
loading...
    loading...
Cat. No.: HY-121872
CAS No.: 222315-88-0
Purity:  ≥95.0%
Research Areas:  

Neurological Disease

DP-b99 is a blood-brain barrier-permeable inhibitor of CYP2C9 and MMP-9, with a Ki value of 4.655 μM against CYP2C9. DP-b99 inhibits CYP2C9 via apparent non-competitive inhibition, mainly chelates pathological Zn 2+ in the membrane environment, attenuates the elevation of intracellular Zn 2+ and Ca 2+ levels, delays seizure onset and reduces seizure severity, and also prevents MMP-9-dependent dendritic spine remodeling, β-dystroglycan cleavage and gelatinase activity. DP-b99 can be used in the research of acute ischemic stroke, epileptogenesis and stroke .
loading...
    loading...
Cat. No.: HY-133116
CAS No.: 435293-66-6
Purity:  97.04%
Target:  

Adrenergic Receptor

Research Areas:  

Neurological Disease

4-Hydroxyatomoxetine is an active metabolite of Atomoxetine. 4-Hydroxyatomoxetine is metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .
loading...
    loading...
Cat. No.: HY-163996
CAS No.: 2886728-09-0
DD202-114 is a potent and selective GLP1R agonist. DD202-114 inhibits hERG with an IC50 of 15.9 μM. DD202-114 exhibits strong CYP2C8 inhibition with an IC50 of 0.22 μM. DD202-114 promotes cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential to be used in the study of type 2 diabetes mellitus (T2DM) and obesity .
loading...
    loading...